2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2173

Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2345

Characterization of Adenosine Deaminase 2 Variants Identified in an International Pediatric Vasculitis Cohort

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2627

Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2346

Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2358

Chest Pain and Angina Pectoris in Rheumatoid Arthritis: Frequency and Prediction of Cardiovascular Mortality

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 1934

Chondrocytes Derived from Mesenchymal Stem Cells Differentiated in the Presence of Plasma-Derived Extracellular Vesicles from Osteoarthritic Patients Express Disease-Related Genes

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2143

Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2435

Circulating Mirnas As Potential Biomarkers of Cardiovascular Disease in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2035

Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2733

Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2133

Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2137

Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2299

Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan：the First Report from the Pediatric Rheumatology Association of Japan (PRAJ)

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2730

Clinical Features and Treatment of Central Nervous System Vasculitis Associated with Acute Posterior Multifocal Placoid Pigment Epitheliopathy

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2555

Clinical History of Psoriatic Arthritis over Four Decades

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].